drugset / Trial / NCT00413166
All-trans Retinoic Acid, and Arsenic +/- Idarubicin
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to learn if the combination of arsenic trioxide (ATO) with ATRA and possibly idarubicin is effective in treating patients with newly-diagnosed APL.
Timeline
- Start
- 2006-12
- Primary completion
- 2016-02
- Completion
- 2016-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gemtuzumab Ozogamicin | Monoclonal antibody | 9 mg/m2 | — |
| Subject | Idarubicin | Small molecule | 12 mg/m2 | Intravenous |
| Subject | Tretinoin | Small molecule | 45 mg/m2 | Oral |
| Subject | arsenic trioxide | Small molecule | 0.15 mg/kg | Intravenous |